
Respirerx Pharmaceuticals Inc.
Get Full AccessDescription
- RespireRx Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of novel drug therapies for the treatment of sleep apnea, drug-induced respiratory depression and other brain-mediated breathing and other disorders.Obstructive Sleep Apnea (OSA), the most common form of sleep apnea, affects 29.4 million Americans according to Frost & Sullivan, but only 5.9 million adults are diagnosed (23.5 million are undiagnosed). OSA, besides causing next day sleepiness which is a major cause of motor vehicle and industrial accidents, and is co-morbid with cardiovascular disease, type 2 diabetes and other conditions. Treatment options are limited and the most effective treatment, the CPAP device has a high non-compliance rate. RespireRx is developing dronabinol, a capsule that is already approved by the U.S. FDA for other indications, for the treatment of OSA. RespireRx believes that patients prescribed a capsule will be more compliant than patients prescribed a CPAP device. Two Phase II clinical trials are complete and we are preparing for Phase III. Dronabinol is D9-THC (delta 9-tetrahydrocannabinol), a synthetic version of a cannabinoid found naturally in marijuana. It is considered a Schedule III drug by the U.S. government and prescriptions are monitored. RespireRx is also developing a 2nd platform, our ampakine platform. Several Phase IIA clinical trials have been completed showing the prevention of opioid induced respiratory depression (opioid induced apnea) without offsetting the desired analgesic (pain killing) effects of the opioid. A human study has also shown evidence of efficacy in central sleep apnea (differs from obstructive sleep apnea). Animal studies in disordered breathing in models of spinal cord injury, Pompe Disease and premature birth were promising. There evidence that are potential opportunities in non-respiratory neurological conditions such as ADHD.
-
Headquarters:126 Valley Road Suite C, Glen Rock, New Jersey, United States
More -
Phone Number: +1 201-444-4947
-
Website: https://www.respirerx.com
-
Employees:3
-
Revenue:$1 - 10M
-
Legal Name:Respirerx Pharmaceuticals Inc.
-
Respirerx Pharmaceuticals Inc.'s Social Media
-
Is this data correct?
-
| NAICS Code: 325412 |
Show More
Frequently Asked Questions regarding Respirerx Pharmaceuticals Inc.
-
Where are Respirerx Pharmaceuticals Inc.'s Headquarters?
Respirerx Pharmaceuticals Inc.'s Headquarters are in 126 Valley Road Suite C,Glen Rock,New Jersey,United States
-
What is Respirerx Pharmaceuticals Inc.'s phone number?
Respirerx Pharmaceuticals Inc.'s phone number is +1 201-444-4947
-
What is Respirerx Pharmaceuticals Inc.'s official website?
Respirerx Pharmaceuticals Inc.'s official website is https://www.respirerx.com
-
What is Respirerx Pharmaceuticals Inc.'s Revenue?
Respirerx Pharmaceuticals Inc.'s revenue is $1 - 10M
-
What is Respirerx Pharmaceuticals Inc.'s NAICS code?
Respirerx Pharmaceuticals Inc.'s NAICS code is 325412
-
How many employees are working in Respirerx Pharmaceuticals Inc.
Respirerx Pharmaceuticals Inc. has 3 employees
-
What is Respirerx Pharmaceuticals Inc.'s Industry?
Respirerx Pharmaceuticals Inc. is in the industry of Biotechnology
-
Who is Respirerx Pharmaceuticals Inc.'s Executive Chairman And Chief Scientific Officer?
Respirerx Pharmaceuticals Inc.'s Executive Chairman And Chief Scientific Officer is Arnold Lippa